Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Cytokinetics: Phase 2 Trial of CK-2127107 in COPD Begins (CYTK, $9.37, Buy)

Overview of COPD

Cytokinetics announced today that it is beginning a phase 2 trial of CK-2127107 in chronic obstructive pulmonary disease…
Read more…

Cytokinetics: Update and Reiteration of My Buy Recommendation (CYTK, $5.54, Buy)

Investment Thesis in Brief
By the end of 2015, Cytokinetics (CYTK) will have tirasemtiv in a phase 3 trial in ALS…
Read more…

Cytokinetics: Updates on Tirasemtiv and Omecamtiv (CYTK, Buy, $7.77)

Investment Overview
I have listened to management presentations at recent brokerage conferences and have then followed up with questions. There are…
Read more…

Cytokinetics: Key Catalysts for 2015 Strongly Support My Buy Recommendation (CYTK, $7.85)

Catalysts for 2015
During the conference call on February 12, 2015 discussing 4Q, 2014 results Cytokinetics discussed key catalysts for 2015…
Read more…

Cytokinetics (CYTK, Buy $5.52) New Collaboration with Astellas on CK-2127107 Greatly Improves Investment Outlook

This deal adds a third leg to the development pipeline at Cytokinetics along with omecamtiv for congestive heart failure and…
Read more…